Pfizer and Valneva's Lyme Disease Vaccine Enters EMA Review Despite Phase 3 Trial Limitations
Pfizer (NYSE:PFE) and Valneva SE (NASDAQ:VALN) announced that the European Medicines Agency has validated their Marketing Authorization Application for PF-07307405, an experimental Lyme disease vaccine. This marks a key regulatory milestone following years of clinical development under their 2020 collaboration agreement. The application is based on Phase 3 trial data showing over 70% efficacy in reducing confirmed cases, though the primary endpoint fell short due to confidence interval limitations. A secondary analysis met the required threshold at 74.8%. The vaccine was generally well-tolerated with no safety concerns reported. Valneva sees strong potential for PF-07307405 as a first-in-class product in an underserved market, while Pfizer is positioned to commercialize it under their partnership terms.
Topics: clinical trials EMA review Lyme disease vaccine development